Company
Every investor coverage indicates participated in a round Mana Communications raised.
Companies Mana Communications acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Mana Communications. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.
QUE Oncology reports its non-hormonal drug Q-122 eased hot flushes in breast cancer patients on endocrine therapy, with Phase II results in The Lancet; the Emory–UniQuest venture is backed by Brandon BioCatalyst and Uniseed.
Brandon Capital's blog covers QUE Oncology's Phase II Q-122 results in The Lancet, showing reduced hot flushes and night sweats in breast cancer patients on endocrine therapy.
Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Auckland University spinout TamoRx has secured NZ$15.25 million to develop a new cancer immunotherapy, in a round led by Brandon Capital alongside the university's Inventors' Fund, with a Callaghan Innovation grant included.
Biotech startup Ankere Therapeutics launches with a $10 million seed round co-led by IP Group and Brandon Capital to develop inflammatory lung disease therapies, building on research from Monash and UniSA scientists.
Also Brandon Capital portfolio·Startup Daily·@AuManufacturing